IOVANCE BIOTHERAPEUTICS INC (IOVA)
US4622601007 - Common Stock
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These
These windows of opportunity aren't likely to remain open for much longer.
Iovance Biotherapeutics is Now Oversold (IOVA)
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Interesting IOVA Call Options For January 2025
Prediction: This Stock Will Beat the Market in 2025
3 Monster Stocks to Hold for the Next 10 Years
Just be ready to ride out some inevitable turbulence along the way.
3 Monster Stocks to Hold for the Next 10 Years
Just be ready to ride out some inevitable turbulence along the way.
Is Iovance Biotherapeutics Stock a Millionaire Maker?
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on...
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
2 Innovative Stocks That Could Deliver Outsize Returns
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
/PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the...
Notable Friday Option Activity: CPRI, IOVA, AGNC
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and...
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance also to Participate in Upcoming November Conferences
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance also to Participate in Upcoming November Conferences...
Notable Two Hundred Day Moving Average Cross - IOVA
Why Iovance Biotherapeutics Stock Triumphed on Thursday
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.
Notable Friday Option Activity: IOVA, MPW, LOVE
First Week of October 18th Options Trading For Iovance Biotherapeutics (IOVA)
IOVA Makes Bullish Cross Above Critical Moving Average
Is Iovance Biotherapeutics Stock a Buy?
The biotech is making important breakthroughs, but is that enough?
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
This biotech's growth story is going to start moving faster, and soon.
Interesting IOVA Put And Call Options For November 15th
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
There's plenty of upside with this stock, but it might take a while to realize.
IOVA Makes Notable Cross Below Critical Moving Average
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Investors should brace for dilution.